Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling.

导出 LinkOut

翻译打印收藏纠错

作者： Yufan,Tan ^[1] ; Xiaoyu,Zhong ^[1] ; Xizhi,Wen ^[2] ; Leyi,Yao ^[3] ; Zhenlong,Shao ^[1] ; Wenshuang,Sun ^[1] ; Jiawen,Wu ^[1] ; Guanmei,Wen ^[1] ; Daolin,Tang ^[1] ; Xiaoshi,Zhang ^[4] ; Yuning,Liao ^[3] ; Jinbao,Liu ^[1]

作者单位： Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, China. ^[1] Institute of Digestive Disease of Guangzhou Medical University, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China. ^[2] Biotherapy Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. ^[3] Department of Surgery, The University of Texas Southwestern Medical Center, Dallas, TX, United States. ^[4]

关键词 BRAF-mutant melanoma ERK MNK1 bilirubin vemurafenib

DOI 10.3389/fonc.2021.698888

PMID 34222023

发布时间 2021-07-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in oncology

2021年11卷

698888页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

检索历史清除